<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709228</url>
  </required_header>
  <id_info>
    <org_study_id>P04793</org_study_id>
    <nct_id>NCT00709228</nct_id>
  </id_info>
  <brief_title>Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)</brief_title>
  <official_title>PREDICT - Prospective Observational Study Of A Cohort Of Na√Øve Patients With Chronic Hepatitis C Infected With Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low
      Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are
      Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) negative at treatment week 4 and week 24. To
      determine the proportion of patients (%) with sustained virological response at 24 weeks
      post follow up treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 500 patients from about 100 sites to be identified as HCV LVL G1 patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of HCV LVL G1 Participants Who Relapsed</measure>
    <time_frame>Week 24 of follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse was defined as undetectable Hepatitis C virus-ribonucleic acid (HCV-RNA) at End of Treatment, but detectable HCV-RNA at Follow-up Week 24.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">496</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PegIntron plus Rebetol</arm_group_label>
    <description>Those with chronic Hepatitis C infected with HCV LVL G1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIntron</intervention_name>
    <description>1.5 ug/kg/week</description>
    <arm_group_label>PegIntron plus Rebetol</arm_group_label>
    <other_name>SCH 054031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebetol</intervention_name>
    <description>800-1200 mg/day</description>
    <arm_group_label>PegIntron plus Rebetol</arm_group_label>
    <other_name>SCH 18908</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for PCR
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to participate

          -  18 years or older, either gender, any race

          -  Must have Hepatitic C Virus Low Viral Load [LCV LVL] (positive, but &lt;600,000 IU/mL on
             the assay used by the individual study site. Only Hepatitis C Virus-Ribonucleic
             acid/quantitative polymerase chain reaction [HCV-RNA/qPCR] assays with results in
             IU/ml are acceptable) AND been diagnosed with Genotype 1

          -  Subject considered suitable for treatment per local label

          -  Investigator considers suitable and subject consents to be treated

        Exclusion Criteria:

          -  Does not show negative polymerase chain reaction [PCR] at week 4

          -  Pregnant women or those who plan to become pregnant or sexual partners of women who
             plan to become pregnant

          -  Subject does not qualify based on contra-indication, special warning, special
             population, and/or pregnancy &amp; lactation section of the Summary of Product
             Characteristics [SmPC]
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, Diago M, Tartaglione MT, Witthoeft T, Yu X, Faruqi R, Chaudhri E, Pedicone LD, Zuckerman E. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response. J Viral Hepat. 2012 Feb;19(2):e120-5. doi: 10.1111/j.1365-2893.2011.01515.x. Epub 2011 Sep 19.</citation>
    <PMID>22239509</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 14, 2015</lastchanged_date>
  <firstreceived_date>June 23, 2008</firstreceived_date>
  <firstreceived_results_date>November 9, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
